Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

Shoulder Innovations, a leader in shoulder replacement technology, today announced the United States Patent and Trademark Office (USPTO) has granted nine new patents over the past 18 months that significantly expand the Company’s intellectual property portfolio.

The newly granted patents cover key areas within shoulder replacement and less invasive surgical techniques, including, among others, glenoid preparation in a single step, total reverse shoulder systems and methods, and porous coated convertible glenoid.

“These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment,” said Rob Ball, CEO of Shoulder Innovations. “This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes.”

Over the past 20 years, Shoulder Innovations has developed a robust intellectual property portfolio around the Inset Glenoid technology and brand that is marked by a continued long life prior to expiration. Specific patents among the newly granted awards adding to the Company’s existing strong IP foundation include:

Glenoid Preparation in a Single Step

  • This patent covers a groundbreaking method of implanting a glenoid implant, which involves reaming two cavities in the glenoid in a single step.

Total Reverse Shoulder Systems and Methods

  • This patent features a reverse shoulder system with a scapular glenoid baseplate and humeral stem, where the baseplate’s axis is angled relative to the stem’s axis.

Porous Coated Convertible Glenoid

  • This patent covers shoulder replacement components and methods utilizing porous fixation rings, enabling the switch from anatomic to reverse articulating surfaces without changing the fixation components.

Shoulder Innovations‘ commitment to advancing shoulder replacement technology is further evidenced by these patents,” said Dr. David Fehnel. “As a shoulder surgeon, I’m thrilled to see these technological developments rapidly making their way into the marketplace, with the goal of helping us provide even more innovative surgical care for our patients.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”